Related Experiment Video
Updated: Nov 16, 2025
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
A New E-Series Resolvin: RvE4 Stereochemistry and Function in Efferocytosis of Inflammation-Resolution
Stephania Libreros1, Ashley E Shay1, Robert Nshimiyimana1
1Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
This study confirms the structure of a new inflammation-resolving compound called RvE4. Researchers used organic synthesis to create RvE4 and compared it to naturally occurring material. They found that synthetic RvE4 had the same UV absorbance, chromatographic behavior, and mass spectrometry patterns as the biogenic form. The compound was tested for its ability to help macrophages clear apoptotic cells and senescent red blood cells. These experiments showed that RvE4 enhances efferocytosis. The study provides direct evidence for RvE4's stereochemical configuration as 5S,15S-dihydroxy-6E,8Z,11Z,13E,17Z. This work clarifies how this new resolvin contributes to inflammation resolution through specific structural features.
Area of Science:
- Inflammation resolution mechanisms in immunology
- Specialized pro-resolving mediator biosynthesis in lipidomics
Background:
Prior research has shown that inflammation resolution involves phagocyte clearance of apoptotic cells. Established knowledge includes the role of specialized pro-resolving mediators in immune cell regulation. No prior work had resolved the stereochemistry of RvE4. This gap motivated investigation into newly identified resolvins. The E-series resolvins remain poorly characterized structurally. Physiologic hypoxia's role in mediator biosynthesis is understudied. Macrophage efferocytosis mechanisms require further clarification. This paper contributes structural confirmation of a novel resolvin's stereochemistry.
Purpose Of The Study:
The aim of this research was to confirm the structure of a newly identified resolvin. The specific problem addressed was the unknown stereochemistry of RvE4. Motivation came from the need to understand how this compound functions in inflammation resolution. The study focused on resolving the molecular configuration of RvE4. Researchers wanted to establish its physical properties. They also aimed to test its biological activity. The work sought to link structure with function in phagocyte responses. This approach helps clarify how resolvins contribute to immune regulation.
Main Methods:
The study used total organic synthesis to create RvE4. Researchers confirmed the compound's structure through UV absorbance analysis. They compared synthetic and biogenic RvE4 using chromatographic behavior. Tandem mass spectrometry fragmentation was employed. Macrophage efferocytosis assays tested human apoptotic neutrophils. Senescent red blood cells were used as additional targets. The experiments measured efferocytosis efficiency. These methods established stereochemistry and biological activity.
Main Results:
Synthetic RvE4 matched biogenic material in UV absorbance. Chromatographic behavior confirmed structural consistency. Tandem mass spectrometry showed identical fragmentation patterns. The compound increased macrophage uptake of apoptotic neutrophils. Efferocytosis of senescent red blood cells was also enhanced. RvE4's stereochemistry was assigned as 5S,15S-dihydroxy-6E,8Z,11Z,13E,17Z. This configuration was verified through multiple analytical methods. The compound demonstrated potent bioactivity in human phagocytes.
Conclusions:
The authors propose that RvE4 has a defined stereochemical structure. They confirm this through synthetic and analytical methods. The compound's bioactivity was validated in human macrophage assays. These findings support RvE4's role in inflammation resolution. The study provides direct evidence for the compound's configuration. The results align with the compound's ability to enhance efferocytosis. The authors suggest that RvE4's stereochemistry is essential to its function. This work clarifies the structure-function relationship of this new resolvin.
Frequently Asked Questions
The authors propose RvE4 has 5S,15S-dihydroxy-6E,8Z,11Z,13E,17Z configuration.
Researchers used UV absorbance, chromatography, and tandem mass spectrometry to verify RvE4's structure.
The compound was tested for its ability to enhance macrophage efferocytosis of apoptotic cells and senescent red blood cells.
UV absorbance, chromatographic behavior, and tandem mass spectrometry fragmentation were used to confirm RvE4's identity.
Human M2 macrophages were tested with apoptotic neutrophils and senescent red blood cells.
The authors propose that RvE4's stereochemistry is essential to its bioactivity in phagocyte responses.
